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Serum characterization and antibody isolation are transforming our understanding of the humoral
immune response to viral infection. Here, we show that epitope specificities of HIV-1–neutralizing
antibodies in serum can be elucidated from the serum pattern of neutralization against a diverse
panel of HIV-1 isolates. We determined “neutralization fingerprints” for 30 neutralizing antibodies
on a panel of 34 diverse HIV-1 strains and showed that similarity in neutralization fingerprint
correlated with similarity in epitope. We used these fingerprints to delineate specificities of
polyclonal sera from 24 HIV-1–infected donors and a chimeric siman-human immunodeficiency
virus–infected macaque. Delineated specificities matched published specificities and were further
confirmed by antibody isolation for two sera. Patterns of virus-isolate neutralization can thus afford
a detailed epitope-specific understanding of neutralizing-antibody responses to viral infection.
Upon infection or vaccination, the adapt-ive immune system typically generatespolyclonal antibody responses that rec-
ognize multiple epitopes (1–3). The serologic
characterization of such polyclonal responses can
inform vaccine design by elucidating which epi-
topes on the antigen are immunodominant and/or
targets of pathogen-specific neutralizing anti-
bodies. Such serologic analysis can further lead
to the isolation of new monoclonal antibodies
that may be of therapeutic value. As a result of
extensive effort to understand the antibody re-
sponse to viral infection, recent years have seen
a surge in the isolation of monoclonal antibodies
against HIV-1, influenza, hepatitis C, and other
viruses (4–15). The link between polyclonal sera
and component monoclonal antibodies, however,
remains complex and difficult to decipher, in part,
because of the extraordinary diversity of circulat-
ing antibodies. Viral genetic diversity can be an
integral mechanism of immune evasion (16–22);
this same diversity may, however, also provide a
means by which to understand antibody responses
(23, 24). Specifically, monoclonal antibodies tar-
geting the same epitope on an antigen are likely
to be affected in a similar way by diversity in that
epitope region.When presentedwith a diverse set
of viral isolates, monoclonal antibodies may thus
exhibit characteristic neutralization patterns or
“neutralization fingerprints” (Fig. 1). Further-
more, neutralization patterns of a polyclonal
serum could be viewed as the combined effect
of the neutralization fingerprints of component
monoclonal antibodies, and, if this relationship
could be deconvoluted, then serum neutraliza-
tion would serve as a predictor of component-
antibody specificity.
To test this conjecture, we selectedHIV-1 be-
cause of its high viral sequence diversity, the avail-
ability of well-characterized sera and antibodies,
and the limited number of sites of vulnerability
targeted by neutralizing antibodies on the HIV-1
spike (Env). These sites encompass the CD4-
binding site (CD4bs), a variable loop V1/V2 site,
and a glycan-V3 site on glycoprotein gp120, and
the membrane-proximal external region (MPER)
on gp41 (4–7, 13, 14, 25–35). The same site of
vulnerability may encompass multiple epitopes
and, as a result, can be targeted by antibodies with
diverse specificities. To determine whether the
neutralization fingerprints of HIV-1 monoclonal
antibodies are a reflection of their epitope spec-
ificities, we utilized neutralization data for a
panel of 34 diverse HIV-1 isolates (table S1), for
30 monoclonal antibodies recognizing diverse
epitopes on HIV-1 Env, and for two variants of
the CD4 receptor (table S2). Neutralization finger-
prints for antibodies known to target similar epi-
topes correlated significantly better (Spearman
correlation) than fingerprints of antibodies tar-
geting different epitopes (fig. S1). On the basis of
the neutralization-correlation values, antibodies
were grouped into 10 clusters (Fig. 2A) (36),
by using a clustering cutoff chosen to agree with
known antibody structures and epitope-mapping
(4–6, 13–15, 25–27, 37–40, 41). Two antibodies,
8ANC195 and HJ16, whose precise epitopes are
currently unknown, clustered separately (5, 15),
whereas all of the other antibody clusters could
be mapped to known sites of Env vulnerability.
Overall, neutralization fingerprints appeared
to exhibit sufficient specificity to successfully dis-
tinguish between antibodies targeting different
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epitopes on the same overall site of vulnerabil-
ity (42). TheMPER site was recognized by two
antibody clusters, each consisting of two anti-
bodies (2F5/m66.6 and 10E8/4E10); this agreed
with known MPER-antibody epitopes (fig. S2)
and demonstrated the dominant contribution of
the recognized epitope, rather than particulars of
antibody orientation, to the antibody-neutralization
fingerprints: 10E8 and 4E10 recognize the same
epitope but use substantially different antibody
heavy- and light-chain orientations (13, 43). The
V1/V2 site was recognized by a single cluster of
PG9-like antibodies. The glycan-V3 site was rec-
ognized by two clusters of antibodies: PGT128-
like antibodies that target a glycopeptide-epitope
and antibody 2G12 that targets a cluster of gly-
cans including N332 (44) on the gp120 surface
(25, 26, 45). Last, the CD4bs was targeted by
at least three clusters, including those of anti-
body b12, CD4, and the VRC01-like antibodies
(27, 38).
VRC01-like antibodies represented the largest
fraction in the analyzed data set and formed the
largest antibody-neutralization cluster; they could
be grouped around VRC01, a prototypical broad
and potent CD4bs antibody capable of neutraliz-
ing 90% of circulating HIV-1 strains (4, 27). The
VRC01-like cluster included antibodies known
to target similar epitopes on gp120, as confirmed
by antibody structures in complex with gp120
(VRC01, VRC03, VRC-PG04, and NIH45-46)
and epitope-mapping experiments (4, 5, 14, 27,40).
Although published epitope maps suggest that
antibodyVRC06 recognizes an epitope composed
of both CD4- and co-receptor–binding sites (46),
the cocrystal structure of VRC06 in complex
with core gp120 revealed a similar mode of
gp120 recognition by VRC06, as compared with
both VRC01 and VRC03 (Fig. 2B), consistent
with the similarity observed for the neutraliza-
tion fingerprints of these antibodies (47). These
results indicate that clustering of antibodies based
on neutralization fingerprints can be an accurate
delineator of antibody-epitope specificity.
To assess whether the neutralization signal
from polyclonal sera could be deconvoluted into
component-antibody specificities, we analyzed
neutralization data for sera from HIV-infected
donors (48). The neutralization fingerprints for
all antibodies within a given cluster were used to
create a single representative neutralization finger-
print for the cluster, resulting in a reference set of
10 epitope-specific neutralization fingerprints,
one for each antibody cluster (fig. S3) (41). The
neutralization pattern for each serumwas taken to
be a linear combination of the reference-set finger-
prints, resulting in an estimate of the relative
contribution to serum neutralization (i.e., neutraliza-
tion prevalence) of the respective component-
antibody specificities as described in (41) and Fig. 1.
For most sera, multiple specificities were pre-
dicted (Fig. 3)—as might be expected from the
polyclonal nature of sera (1–3). To evaluate the
neutralization-based serum-epitope predictions,
we compared themwith component-antibody epi-
topes determined by other experimental means.
We first compared predictions for which serum-
neutralization specificities were already known
through antibody isolation or extensive epitope
mapping. The neutralization-based prediction for
donor 45, the source of VRC01 and other VRC01-
like antibodies (4), indicated a strong signal for
VRC01-like antibodies (Fig. 3A) (49). The pre-
diction for donor N152, the source of antibody
10E8 (13), showed a dominant signal for the
10E8-like cluster (Fig. 3A). Furthermore, lon-
gitudinally sampled sera from donor CAP256
showed a PG9-like signal at each of four time
points, both by extensive experimental epitope
mapping (50) and computational predictions
(Fig. 3B). Last, sera froma chimeric simian-human
immunodeficiency virus (SHIV)–infected ma-
caque showed a dominant PGT128-like signal at
each of four time points (Fig. 3C), in agreement
with published epitope-mapping experiments
(51). The neutralization-based method for delin-
eating component-antibody epitopes was thus
successful in identifying major antibody responses
for sera with confirmed specificities.
Next, we applied our method to prospectively
delineate specificities for sera from 21 HIV-1–
infected donors (52) and compared the results to
(standard) experimental serummapping data (Fig.
3D): Published assays were used to map serum
antibody specificity toward the CD4bs, V1/V2,
glycan-V3, and MPER regions (41, 53). The de-
gree of correspondence between the neutralization-
based prediction method and standard mapping
varied for different sera, with discrepancies partly
attributable to known limitations in current stan-
dard mapping assays (54) (table S4). Nonetheless,
the agreement between the two methods was rea-
sonably good, with at least one of the top two
neutralization-delineated specificities identified
by standard mapping in ~85% of the tested sera
(Fig. 3E) (55).
To further validate our predictions, we se-
lected two sera with different predicted specific-
ities and prevalence levels: (i) serum from donor
127/C predicted to have a dominant VRC01-like
specificity with a prevalence level of 0.60 and
(ii) serum from donor N27 predicted to have a
PGT128-like specificity with a prevalence level
of 0.33 (Fig. 3D). We cloned CD4bs antibodies
from donor 127/C peripheral bloodmononuclear
cells (PBMCs) by using an antigen-specific pro-
tein probe (RSC3), as described previously (4).
We identified two somatic variants, VRC23 and
VRC23b that showed strong similarity to other
VRC01-like antibodies by germline-gene usage,
Fig. 1. Definition of antibody neutralization fingerprints and deter-
mination of antibody specificities from serum patterns of neutraliza-
tion. The neutralization fingerprint for an antibody on a panel of diverse viruses
may contain sufficient information to define both antibody epitope andmolecular
specificities of recognition. Here, we show how information from a neutralization
matrix can be transformed to delineate epitope specificity. First, a database of
neutralization fingerprints for known antibodies can be constructed on the basis of
clustering of antibody-neutralization behavior: The neutralization fingerprints for
antibodies (columns: A1 to A6) are shown in a neutralizationmatrix [first (leftmost)
panel], with colors representing neutralization potencies against specific viruses
(rows: V1 to V7); the correlations between antibody neutralization fingerprints
(second panel) can help form epitope-specific antibody clusters (third panel). The
resultant epitope-specific neutralization fingerprints (fourth panel) can be used to
interrogate patterns of neutralization from polyclonal sera. Deconvolution of the
serum-neutralization pattern (last panel) into epitope-specific fingerprints iden-
tifies epitope specificity of the component antibodies (fifth panel).





































sequence signature, binding characteristics, and
neutralization (Fig. 4A and figs. S4 to S7) (41).
Furthermore, the crystal structure of VRC23 in
complex with gp120 revealed substantial simi-
larities with the mode of gp120 recognition by
VRC01 and other VRC01-like antibodies (56),
confirming the neutralization-based prediction
of VRC01-like antibody specificity in serum
127/C. By comparison, standard experimental
serummapping showed borderline evidence for
CD4bs activity, with RSC3-based inhibition of
127/C neutralization reaching only 20% (fig.
S11). For donor N27, standard serummapping
(Fig. 3D) indicated the presence of glycan-reactive
antibodies.We used single B cell culture (5, 13, 41)
and recovered one neutralizing antibody, VRC24
(fig. S4). Binding and neutralization assays for
VRC24 suggested a glycan-V3 epitope (figs. S12
to S14), with general similarity to (but also some
differences from) other antibodies in the PGT128-
like cluster. Thus, for both donors 127/C and
N27, we successfully confirmed the existence
of antibodies with specificities predicted by the
neutralization-based method. Furthermore, the
neutralization fingerprints for antibodies VRC23
and VRC24 clustered appropriately—within the
VRC01-like cluster for VRC23 and most closely
to (though not fully intermingled with) the PGT128-
like cluster for VRC24 (Fig. 4B)—which dem-
onstrated that, in addition to delineating serum
specificity, neutralization fingerprints allow for pro-
spective prediction ofmonoclonal antibody epitopes.
Analysis of sera from HIV-1–infected do-
nors and, more recently, from SHIV-infected ma-
caques is revolutionizing our understanding of
the ability of the humoral immune system to rec-
ognize and to neutralize HIV-1 (29–34). Such
analysis generally begins with an assessment
of serum neutralization on small or moderately
sized virus panels (29, 57) and then proceeds
with epitope mapping and monoclonal antibody
isolation. The ability to delineate component-
antibody neutralization specificities directly from
serum-neutralization data potentially transforms
this process, by providing a computational short-
cut for procedures of standard epitope mapping,
monoclonal antibody isolation, and crystal struc-
ture determination of the epitope (58). Such a
Fig. 2. Neutralization-based clustering of HIV-1 antibodies. (A)
Antibody-antibody neutralization-correlation matrix. A set of HIV-1–neutralizing
antibodies along with two variants of CD4 were assessed for neutralization on a
panel of 34 diverse HIV-1 isolates. Input from six neutralization panels (tables S5
and S6) were used to define this correlationmatrix and are indicated by superscripts
a through f next to each antibody name, with several antibodies tested on multiple
panels. Correlation results are shown in heat-map representation from 0.5 (yellow)
to 1.0 (dark brown) and were used as input for antibody clustering. The intersection
of the dotted vertical line with horizontal lines in the clustering tree defines the
10 antibody clusters: VRC01-like (maroon), PG9-like (green), PGT128-like (blue),
2F5-like (light blue), and 10E8-like (aqua), as well as separate clusters for b12,
CD4, 2G12, HJ16, and 8ANC195. Antibody order was based on the clustering tree.
(B) Comparison of gp120 recognition by antibodies VRC03 and VRC06, shown as
epitope and 90 degree–rotated complex. Although VRC03 and VRC06 display
substantial phenotypic differences (46), their neutralization fingerprints are highly
correlated, and cocrystal structures reveal the same gp120 mode of recognition.





































short-cut should afford a more rapid and less ar-
duous delineation of serum component–antibody
epitopes and may be especially useful for studies
in which sample volumes are limited. Two de-
velopments have been key to the success of the
method and are likely to work synergistically
to improve such neutralization-based delinea-
tion. First, application of robotic technology to
neutralization assessment has made data from
HIV-1–neutralization panels easier to obtain
(14, 57, 59, 60). Second, advances in monoclonal
antibody identification have allowed for the re-
cent isolation of many effective HIV-neutralizing
antibodies, and structural analysis has delineated
their sites of recognition (20, 35, 61); although
Fig. 3. Delineation of antibody specificities in HIV-1 sera with broadly
neutralizing activity. For each serum, the predicted relative prevalence of
the different reference-set antibody clusters (colored as in Fig. 2) is shown
as a heat map, with darker intensity (higher fractional number) correspond-
ing to a stronger neutralization signal (predicted prevalence level) by the
respective antibody cluster. Numbers in each row add up to 1.00, with num-
bers less than 0.01 not shown. Serum neutralization breadth is shown for
the specific virus panels used, and average potency provided as geometric
mean inhibitory dilution (ID50). Predictions for (A) serum from donor 45 (the
source for antibody VRC01) and from donor N152 (the source for antibody
10E8), (B) sera from four different time points (years 1 to 4) postinfection
from donor CAP256, and (C) sera from four different time points (weeks 40,
61, 81, and 100) postinfection from macaque CE8J. To the right of (A) to (C)
are schematics of the putative locations on the HIV-1 Env trimer of the epi-
topes identified in the neutralization-based predictions and previously con-
firmed to be targeted by antibodies in the sera. (D) Neutralization-based
predictions (left) and standard experimental mapping data (right) for an
additional set of 21 sera (rows) and 10 epitopes (columns). Epitope groups
(bold) for the experimental mapping data were defined on the basis of the
assays used; the respective closely matching neutralization-based epitope
clusters were grouped accordingly (shown in parentheses). Epitope groups
are marked with a plus sign (+) if predicted by the mapping assays to be
present in a given serum or with a “-” otherwise. (E) Concordance between
neutralization-based and standard serum mapping.





































currently identified sites are likely to dominate
the neutralizing antibody response, highly effec-
tive antibodies against unknown and/or less-well-
characterized epitopes continue to be identified
(53, 62). Generally, epitope delineation based on
neutralization fingerprintsmay provide a transform-
ative strategy for screening sera or characterizing
antibody specificities induced upon infection or
vaccination against HIV-1 as well as other viruses.
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Brain plasticity as a neurobiological reflection of individuality is difficult to capture in animal
models. Inspired by behavioral-genetic investigations of human monozygotic twins reared
together, we obtained dense longitudinal activity data on 40 inbred mice living in one large
enriched environment. The exploratory activity of the mice diverged over time, resulting in
increasing individual differences with advancing age. Individual differences in cumulative
roaming entropy, indicating the active coverage of territory, correlated positively with individual
differences in adult hippocampal neurogenesis. Our results show that factors unfolding or
emerging during development contribute to individual differences in structural brain plasticity
and behavior. The paradigm introduced here serves as an animal model for identifying mechanisms
of plasticity underlying nonshared environmental contributions to individual differences in behavior.
Plasticity, or the reciprocal interaction be-tween brain structure and function, drawson genetic and nongenetic sources of var-
iation and forms the neurobiological basis of
individuality. Behavioral-genetic studies with hu-
mans provide statistical tools for estimating the
additive and interactive contributions of genetic
and environmental variations to individual differ-
ences in behavioral development (1). In the case
of monozygotic twins reared together, sibling
differences reflect the influence of individual re-
sponses, based on the same genetic makeup, to
a nominally identical environment. Somewhat
paradoxically, this source of variation is generally
referred to as the “nonshared environment” in be-
havior genetics.As Turkheimer has noted, “exactly
what the nonshared environment consists of has
been amatter ofmystery and controversy for some
time” [(2) p. 826].We developed an animal model
for studying the nonshared environment and exam-
ined its effects onbehavioral andneural development.
In rodents, enriched environments are among
the tools of choice for addressing the influence of
a given environment on individuals with identical
genetic background (3, 4). However, with some
exceptions [(5), see also (3, 6)] the emergence
of experience-based individual differences within
groups of genetically identical animals exposed
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polyclonal sera from HIV-infected patients.
developed that could successfully delineate the neutralization specificity of antibodies present in 
sera that contain particular bNAbs show characteristic patterns of neutralization. An algorithm was
advantage of the fact that only four sites on the HIV viral envelope protein seem to bind bNAbs, and 
 (p. 751) tooket al.Georgiev could bind to VRC01-class bNAbs and to their germline precursors. 
March; see the cover) used computational analysis and in vitro screening to design an immunogen that 
 (p. 711, published online 28et al.Jardine antibodies often does not bind to the germline sequence. 
). However, because of extensive somatic hypermutation, the epitope bound by theseCroweby 
information to inform the design of vaccines that are able to induce such antibodies (see the Perspective
the gp120 envelope protein of HIV-1 have been discovered. The goal of this work is to use this 
In the past few years, several highly potent, broadly neutralizing antibodies (bNAbs) specific for
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